Evidence map›Paper›PMID 38526743›Full record

ArticleExperimental brain research2024

[

Imane Frouni, Esther Kim, Judy Shaqfah, Dominique Bédard, Cynthia Kwan, Sébastien Belliveau, Philippe Huot

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental brain research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. GlyT1 (SLC6A9) inhibition in neurological and psychiatric disorders.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Imane FrouniDépartement de Pharmacologie et Physiologie, Université de Montréal, Montreal, QC, Canada.ORCID http://orcid.org/0000-0001-6779-8713
Esther KimNeurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), 3801 University St, Montreal, QC, H3A 2B4, Canada.
Judy ShaqfahNeurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), 3801 University St, Montreal, QC, H3A 2B4, Canada.
Dominique BédardNeurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), 3801 University St, Montreal, QC, H3A 2B4, Canada.
Cynthia KwanNeurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), 3801 University St, Montreal, QC, H3A 2B4, Canada.ORCID http://orcid.org/0000-0002-3878-6745
Sébastien BelliveauNeurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), 3801 University St, Montreal, QC, H3A 2B4, Canada.
Philippe HuotDépartement de Pharmacologie et Physiologie, Université de Montréal, Montreal, QC, Canada. philippe.huot@mcgill.ca.ORCID http://orcid.org/0000-0002-5464-8334
Montreal Neurological Institute and Hospital · CA

Funding

Michael J. Fox Foundation for Parkinson's Research 15166
6 · The paper itself

Abstract

L-3,4-dihydroxyphenylalanine (L-DOPA) is the main treatment for Parkinson's disease (PD) but with long term administration, motor complications such as dyskinesia are induced. Glycine transporter 1 (GlyT1) inhibition was shown to produce an anti-dyskinetic effect in parkinsonian rats and primates, coupled with an improvement in the anti-parkinsonian action of L-DOPA. The expression of GlyT1 in the brain in the dyskinetic state remains to be investigated. Here, we quantified the levels of GlyT1 across different brain regions using [

Indexed as

BrainGlycine Plasma Membrane Transport ProteinsOxidopamineAnimalsDisease Models, AnimalFunctional LateralityMaleParkinsonian DisordersRatsRats, Sprague-DawleySarcosineTritiumGlycine Plasma Membrane Transport ProteinsOxidopamine(R)-(N-(3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl))sarcosineSarcosineSlc6a9 protein, ratTritium[3H]-NFPS6-OHDA-lesioned ratAutoradiographyDyskinesiaGlyT1Org-25,935Parkinson’s disease

Identifiers

PMID38526743
PMCPMC11078860
OpenAlexW4393155045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.